secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quanterix Corp (QTRX)
CIK:        0001503274
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001503274-26-000011
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quanterix Q4 revenue $43.9M (+25% YoY); guides 2026 rev $169-174M, cash flow breakeven H2
--------------------------------------------------------------------------------

- Q4 revenue $43.9M vs $35.2M prior year (+25%); full-year revenue $138.9M (+1% YoY).
- GAAP gross margin 45.7% (Q4) and 46.8% (FY); adjusted gross margin 50.0% (Q4) and 47.3% (FY).
- Adjusted EBITDA loss of $7.9M in Q4 and $44.9M for FY; cash balance $121.6M.
- Initial 2026 guidance: revenue $169-174M, adjusted gross margin 49-53%, cash ~$100M year-end.
- Filed 510(k) for Alzheimer's blood test; CMS set reimbursement rate of $897 for LucentAD Complete.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503274/000150327426000011/0001503274-26-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503274/000150327426000011/qtrx-20260302.htm
  HTML page:      https://secwatch.observer/filing/0001503274-26-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer